A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

February 15, 2028

Study Completion Date

March 28, 2031

Conditions
Cardiomyopathy, Hypertrophic
Interventions
DRUG

Mavacamten

Specified dose on specified days

DRUG

Placebo

Specified dose on specified days

Trial Locations (47)

2145

Local Institution - 0020, Sydney

3168

Local Institution - 0042, Clayton

8950

Local Institution - 0014, Barcelona

11042

Local Institution - 0010, New Hyde Park

13353

Local Institution - 0018, Berlin

16147

Local Institution - 0051, Genova

27705

Local Institution - 0039, Durham

28046

Local Institution - 0025, Madrid

28204

Local Institution - 0015, Charlotte

33604

Local Institution - 0026, Pessac

38105

Local Institution - 0034, Memphis

43205

Local Institution - 0029, Columbus

45229

Local Institution - 0019, Cincinnati

48109

Local Institution - 0002, Ann Arbor

50100

Local Institution - 0016, Florence

63110

Local Institution - 0037, St Louis

75015

Local Institution - 0022, Paris

77030

Local Institution - 0054, Houston

78712

Local Institution - 0045, Austin

80131

Local Institution - 0027, Napoli

80636

Local Institution - 0006, Munich

35294-0004

Local Institution - 0017, Birmingham

85016-7710

Local Institution - 0050, Phoenix

90027-6062

Local Institution - 0032, Los Angeles

90095-8344

Local Institution - 0008, Los Angeles

94304-1601

Local Institution - 0033, Palo Alto

92123-4223

Local Institution - 0044, San Diego

80045-7106

Local Institution - 0038, Aurora

33701-4634

Local Institution - 0031, St. Petersburg

30329-3117

Local Institution - 0053, Atlanta

60637-1447

Local Institution - 0013, Chicago

46202-5272

Local Institution - 0009, Indianapolis

02115-5724

Local Institution - 0043, Boston

07960

Local Institution - 0052, Morristown

10029-6574

Local Institution - 0024, New York

10032-1559

Local Institution - 0036, New York

10467-2403

Local Institution - 0040, The Bronx

44195-0001

Local Institution - 0001, Cleveland

19104-4319

Local Institution - 0030, Philadelphia

15224-1334

Local Institution - 0005, Pittsburgh

84113-1103

Local Institution - 0003, Salt Lake City

22908-0816

Local Institution - 0012, Charlottesville

T6G 2R7

Local Institution - 0041, Edmonton

M5G 1X8

Local Institution - 0046, Toronto

D12 N512

Local Institution - 0047, Dublin 12, D12 N512

BT12 6BA

Local Institution - 0049, Belfast

WC1N 3JH

Local Institution - 0007, London

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06253221 - A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Biotech Hunter | Biotech Hunter